STOCK IN FOCUS: Piramal Pharma

Q3 Results: Net Profit down 63% YoY at ₹3.7 Cr, down 84% QoQ.

Revenue up 13% YoY at ₹2,204 Cr, down 2% QoQ.

EBITDA up 26% YoY at ₹338 Cr, down 1% QoQ.

Margins at 15.36% vs 13.7% YoY, 15.2% QoQ.

#PiramalPharma #Q3Results #ProfitDecline #RevenueGrowth #StockMarket #FinancialResults
#PiramalPharma #Q3Results #ProfitDecline